PAX4 antibody
Contáctenos para saber el precio
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Name
PAX4 antibody
Category
Primary Antibodies
Provider
FineTest
Reference
FNab10171
Tested Applications
ELISA, IHC
Documentos del producto
Especificaciones del producto
| Category | Primary Antibodies |
| Immunogen Target | Paired box protein Pax-4 (PAX4) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | IHC: 1:50-1:500 |
| Clonality | polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Observed MW | 38 kDa |
| Purity | ≥95% as determined by SDS-PAGE |
| Purification | Immunogen affinity purified |
| Size 1 | 100µg |
| Form | liquid |
| Tested Applications | ELISA, IHC |
| Storage | PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.) |
| UniProt ID | O43316 |
| Gene ID | 7849 |
| Alias | KPD, MODY9 |
| Background | Antibody anti-PAX4 |
| Status | RUO |
| Note | Mol. Weight 38 kDa |
Background
PAX4 is a transcription factor involved in the development and differentiation of pancreatic β-cells, essential for insulin production. PAX4 plays a critical role during embryonic development by repressing the α-cell lineage and promoting the specification of endocrine progenitor cells into β-cells within the pancreas. It directly regulates genes involved in β-cell identity, proliferation, and survival. Mutations in PAX4 are associated with monogenic forms of diabetes, such as maturity-onset diabetes of the young (MODY) and other metabolic disorders due to insufficient insulin production. PAX4 expression is tightly regulated, and its overexpression can influence β-cell regeneration, offering therapeutic potential for diabetes treatment. Knockout models show impaired β-cell development, hyperglycemia, and defective glucose homeostasis, underscoring PAX4's pivotal role in pancreatic endocrine development, insulin regulation, and diabetes pathology.